e& achieves AED 16.9 billion consolidated revenue growing 18.7% YoY in Q1 2025
Consolidated net profit increased to AED 5.4 billion, reflecting a 129.9 per…
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results…
